Strs Ohio Decreases Holdings in Codexis, Inc. (NASDAQ:CDXS)

Strs Ohio trimmed its holdings in shares of Codexis, Inc. (NASDAQ:CDXS) by 14.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 252,500 shares of the biotechnology company’s stock after selling 42,900 shares during the period. Strs Ohio owned 0.36% of Codexis worth $770,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the business. FMR LLC boosted its position in Codexis by 153.7% during the 3rd quarter. FMR LLC now owns 4,335,580 shares of the biotechnology company’s stock worth $8,194,000 after purchasing an additional 2,626,400 shares during the period. Assenagon Asset Management S.A. lifted its holdings in Codexis by 156.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,753,443 shares of the biotechnology company’s stock worth $3,314,000 after buying an additional 1,071,002 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in Codexis by 25.8% in the 3rd quarter. Acadian Asset Management LLC now owns 949,916 shares of the biotechnology company’s stock worth $1,793,000 after buying an additional 194,898 shares in the last quarter. Kent Lake Capital LLC acquired a new position in Codexis in the 3rd quarter worth $1,026,000. Finally, Paradigm Capital Management Inc. NY lifted its holdings in Codexis by 66.7% in the 3rd quarter. Paradigm Capital Management Inc. NY now owns 500,000 shares of the biotechnology company’s stock worth $945,000 after buying an additional 200,000 shares in the last quarter. 78.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have commented on CDXS. StockNews.com upgraded shares of Codexis to a “sell” rating in a report on Tuesday, March 5th. Benchmark upgraded shares of Codexis from a “hold” rating to a “buy” rating and set a $9.00 price objective on the stock in a report on Thursday, February 29th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $6.80.

Codexis Stock Performance

Shares of Codexis stock opened at $2.80 on Thursday. The firm has a market cap of $196.84 million, a PE ratio of -2.52 and a beta of 2.01. The firm’s 50-day simple moving average is $3.32 and its 200-day simple moving average is $2.72. Codexis, Inc. has a 1 year low of $1.45 and a 1 year high of $4.91.

Codexis (NASDAQ:CDXS) last issued its earnings results on Wednesday, February 28th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.18. The business had revenue of $26.56 million for the quarter, compared to analyst estimates of $24.73 million. Codexis had a negative net margin of 108.69% and a negative return on equity of 47.58%. On average, equities analysts predict that Codexis, Inc. will post -0.6 earnings per share for the current year.

Codexis Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.